Head-to-head evidence
Olanzapine (TV-44749) vs Paliperidone palmitate (Invega Hafyera)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Olanzapine (TV-44749)
Developed by Teva Pharmaceutical Industries
NCT05693935 · Phase 3 · completed
The 675-participant study was randomized, quadruple-blind, and placebo-controlled, with approximately 165 to 169 participants per blinded treatment group. Its primary clinical endpoint, change in PANSS total score at week 8, was significantly better with each TV-44749 dose than with placebo (all adjusted p<0.0001), supporting a strong evidence rating for the blinded efficacy comparison.
Paliperidone palmitate (Invega Hafyera)
Marketed by Johnson & Johnson
NCT03345342 · Phase 3 · completed
After an open-label stabilization phase, 702 participants were randomized to six-month or three-month paliperidone palmitate and treated double-blind with matching injections, including placebo injections to preserve masking. The primary endpoint was the clinical outcome of time to relapse, but the registry reports that the median was not estimable in either group and does not provide a p-value or confidence interval, so the result cannot be classified as clearly met or missed.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olanzapine (TV-44749)'s landscape · Paliperidone palmitate (Invega Hafyera)'s landscape